Paper IV of the present series reviewed the mechanism by which helenine, an antibiotictike substance derived from Penicilliura funiculosum, exerts its antiviral effect. It was concluded that helenine is not directly virucidal but exerts its effect through mobifization of host factor(s) (1). This conclusion was based on the observation that protection of mice against Semliki Forest virus challenge was not evident until 6 to 48 hr after the administration of helenine; injection of helenine at the time of, or shortly after infection, had tittle or no protective effect. A similar period of pretreatment was necessary for helenine to inhibit the cytopathogenic effect of Semliki Forest virus in chick embryo fibroblast cell culture (2). Moreover, animals which survived a viral challenge because pretreated with helenine proved fully susceptible when rechallenged with the same agent, a fact perhaps indicative of interference with replication of complete, antigenically potent virions, capable of eticiting acquired immunity. Thus the protective activity of helenine is analogous to that observed with viral interference, an antiviral effect mediated by interferon (3, 4) . Interferon is not demonstrable in normal cells but appears after a characteristic lag period several hours after its induction, at which time cellular resistance to virus is apparent (5). Furthermore, interferon exerts its effect in the viral replication cycle prior to assembly of complete viral particles, thereby inhibiting the formation of viral antigens (4).
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The present paper reports evidence that the administration of helenine is followed by the formation in cultures of L-929 cells, or in intact mice, of an inhibitor of viral replication which fulfills the major biological and physicochemical criteria for interferon.
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Materials and Methods
Tissue Cul~re.--L-929 cells (NCTC clone 929) were obtained from the South Jersey Medical Research Foundation, Camden, New ~ersey, and grown in 250 ml plastic flasks (Falcon Plastic Company, Los Angeles) in medium 199 fortified with 5% heat-inactivated calf serum, in the presence of penicillin (100 units/ml) and streptomycin (100/~g/ml). The cells were then resuspended for transfer by trypsinization (trypsin 0.05%, Difco Laboratories, Inc., Detroit). Repeated testing failed to demonstrate pleuropneumonialike organisms (PPLO).
Virus.--Vesicular stomatitis virus (VSV) (Indiana strain) served as the indicator virus in interferon titrations. In order to obtain plaques of uniform size, which would facilitate the assessment of plaque number, the seed virus was isolated by plaque purification and propagated in L-929 cells. Titers in the order of 107/0.2 ml were uniformly obtained. In interferon fitrafions the seed virus was diluted in medium 199 with 0.1% bovine albumin to give approximately 50 plaque-forming units (PFU)/0.2 ml.
Animals.--Male mice of the MF-1 pathogen-free strain (supplied by the Manor Farms, Staatsburg, New York) were chosen for use to insure a greater uniformity of response and to reduce the possibility of endogenous infections, since it has been demonstrated that certahi bacteria can elicit the formation of interferonlike substances (6) . In every experiment, mice 8 to 9 wk of age were employed, weighing on the average 32 to 36 g. At the beginning of each, the mice were placed in individual cages.
ttdenine.--Several lots of helenine were employed. They were prepared from broth cultures of Pen~illium ]uniculosum according to the methods described previously (1) . When tested for protection against viral challenge, they were found to be uniformly effective in that all pretreated mice survived subcutaneous challenge with 10 to 1000 lethal doses of Semliki Forest virus whereas all untreated mice succumbed. The helenine preparations were stored at -20°C until ready to use at which time they were quick-thawed (and subsequently stored at 4°C).
Induvtion o] the Inhibitor in Tissue Culture.--When a complete monolayer (consisting of approximately 107 cells) was established in a 250 ml plastic flask, growth medium was removed and 1.0 ml of undiluted helenine added. A control flask was similarly treated with No. 199 maintenance medium. The bottles were incubated at 37°C for 30 rain to permit absorption of helenine and then 20 ml of medium 199 was added to each bottle and incubation at 37°C resumed. 24 hr later the tissue culture fluids were harvested and sterility tests carried out in sheep blood agar and thioglycollate broth.
lnduvtion of the Inhibitor in Mice.--Mice were injected into the tail vein with 0.2 or 0.5 ml of undiluted helenine or, for control purposes, with equal amounts of saline, utilizing 1 ml syringes and 26 gauge, IN inch disposable needles. Bloods were collected from groups of 6 mice at indicated time intervals, under nembutal anesthesia, by cardiac puncture. After clotting, the sera were separated by centrifugation and stored at 4°C. Organ extracts were prepared by homogenizing pooled organs as 10% (by wet weight) suspensions in medium 199 with 0.1% bovine albumin and they were clarified by centrifugation at 10,000 m,~ for 10 rain in a Lourdes centrifuge.
Titration of the Inhibitor.--Inhibitor titration was carried out according to a modification of Wagner's 50% plaque reduction method of interferon assay (7) . L-929 cells were grown in medium 199 with 5% inactivated calf serum and antibiotics in 60 mm plastic dishes (Falcon). The dishes were seeded with 0.5 X 106 cells each and incubated in a 5% CO2 atmosphere at 37°C. Complete monolayers were achieved in 48 hr. Specimens consisting of sera, organ extracts, or tissue culture fluids were serially diluted by 2-or 4-fold in medium 199 with 0.1% bovine albumin. Cell monolayers were then overlaid with 2 ml aliquots of the diluted samples and incubated at 37°C for 6 hr. Then these fluids were removed, monolayers were washed with phosphate-buffered saline (PBS) (without Ca ++ or Mg++), and challenged with an esti-mated 50 PFU of VSV. After 30 rain absorption at 37°C, 5 mi of 1% agar (Ionagar, Oxoid Division, Consolidated Laboratories, Chicago Heights, Illinois) with medium 199 and 1% heat-inactivated calf serum was added and the dishes were reincubated for 48 hr. At that time the cell monolayers were stained with neutral red (0.02%) in medium 199 for 3 hr and the plaques were counted.
The fiter of the inhibitor was taken as the reciprocal of the highest dilution giving 50% reduction in the plaque number, as compared with the control number, and expressed in terms of units per 2 ml. When the desired degree of plaque reduction fell between two dilutions, the titer was determined by interpolation. In replicate titmtlons of the same sample, the titers did not differ by more than 2-fold, in most instances. 
RESU'LTS
Induction of the Ink~tor in Tissue Culture.--When helenine was added to a monolayer of L-929 cells in a flask (as described above), and the tissue culture fluid obtained 24 hr later was assayed, an inhibitor fiter of 160 units was obtained in one experiment. In another, the inhibitor titer was 178 units. The control fluids had no inhibitory activity (Table I) .
Induction of the Inkibitor in Mice.--In a preliminary experiment, a serum pool from a group of 6 mice inoculated 16 hr previously with 0.2 ml of helenine was found to have an inhibitor titer of 538 units, whereas pooled control serum had no inhibitory activity at a dilution of 1/4. In order to determine the kinetics of the appearance of inhibitor in the serum, the following experiment was conducted.
Groups of 6 mice were injected into the tail vein with 0.2 ml of helenine and serum samples were collected at 2, 6, 12, 16, 24, and 48 hr. Control groups which received saline were bled at 6 and 24 hr after injection.
The experimental results of these tests are summarized in Table II . Inhibitor appeared at 2 hr, was demonstrable for 24 hr, but none was present after 48 hr. The highest levels were obtained at 12 and 16 hr when the titer was 630 units. Control sera showed no inhibitory activity at a dilution of 1/4.
The Effect of Different Doses of Helenine on the Formation of the Inkibitor.--
When increasing amounts of helenine (0.05 ml, 0.2 ml, and 0.5 ml) were inocu-580 ANTIVIRAL SUBSTANCE FROM PENICILLIITM FUNICULOSITME. V lated intravenously into mice, progressively greater amounts of inhibitor were demonstrable 16 hr later. The highest response, corresponding to 1994 units, was achieved with the 0.5 mi dosage (Table III) . One tenth of this dose (0.05 ml) of helenine resulted in an inhibitor level of 10 units. The dose of 0.2 ml employed in most experiments resulted in a titer of 600 units. These data, though preliminary, provide evidence for a dose-effect curve with helenine administration. Inhibitor Concentrations in Tissue Extracts.--Repeated attempts were made to determine the presence of the inhibitor in tissue extracts from mice injected with helenine. When 10 % homogenates of spleen, lung, and liver, obtained at 6 and 16 hr after injection of helenine, were assayed, there was a decrease in the plaque size and number at the lowest dilutions (1/4 and 1/8), the greatest decrease occurring with the splenic extracts. The degree of plaque suppression, however, was only slightly greater than that obtained with extracts from control animals. The inhibitor concentrations in the pooled sera from these animals were 112 units at 6 hr and 278 units at 16 hr.
In experiments to be reported in a separate communication (9) , employing Newcastle disease virus (NDV) as interferon-inducer in mice, comparable tissue homogenates did contain significant amounts of interferon. Since much higher serum interferon concentrations were achieved in these experiments, however, it is felt that the borderline amounts of interferon found in tissue extracts in the present study may merely represent variations in the degree of interferon stimulation by the two different inducers. Altematively other sites, such as lymph nodes, which were not examined in the present study, may be the main sites of the interferon formation induced by helenine.
Physicochemical and Biological Characterization of the Helenine-Induced Inhibitor.--A number of studies were conducted in order to determine if the helenine-induced inhibitor, either as found in tissue culture or in the sera of mice, fulfilled the basic criteria for the definition of interferon (Table IV) . The inhibitor was shown to be acid-stable and nondiallzable on dialysis at 4°C against a pH 2.0 glycine buffer for 24 hr, followed by dialysis for 24 hr against a pH 7.2 phosphate buffer (to restore neutrality). It was completely inactivated when incubated with 500 #g/ml of crystalline trypsin for 1 hr at 37°C. It did not sediment when centrifuged at 105,000 g for 2 hr. It was almost completely inactivated by incubation at 56°C for 30 min, as has been reported previously for mouse interferon both in tissue culture (8) and serum preparations (6) . When titrated in a cell line derived from a heterologous species, i.e., a human conjuncfival cell variant (clone 1-5C-4) (10), it had no inhibitory effect. Finally, the inhibitor was not directly virucidal as indicated by the absence of any decrease in plaque-forming units when VSV was incubated either with tissue culture or serum preparations.
DISCUSSION
From all of the data that have been presented, it is concluded that the inhibitor fulfills the major criteria for identification as interferon.
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A number of nonviral substances have been shown to be capable of inducing interferonlike inhibitors. These include phytohemaggiutinin (11) , bacteria and bacterial endotoxins (6) , nucleic acids of viral and nonviral origins (12) , and statolon, a substance derived from Penicillium stoloniferum (13, 14) .
Studies on these nonviral but virus-inhibiting interferons have revealed that some of them differ in several important respects from the "classical" interferon induced by viruses. For example, interferon formed in response to endotoxin can only be called forth in an intact animal, not in tissue culture, it has a higher molecular weight, 85,000 to 89,000 compared to 25,000 to 31,000 for most viral interferons (15) , and it is demonstrable in peak titer 2 hr after endotoxin administration but is almost undetectable by 12 hr (6) . Statolon-induced interferon, on the other hand, possesses most of the characteristics of viral interferon in that it can be produced both in tissue culture (13) and in vivo systems (14) ; the kinetics of its appearance in the serum are similar to those of viral interferon and its molecular weight when produced in tissue culture is similar to that of NDV-induced tissue culture interferon (14) . The serum interferon induced by statolon, however, does differ from virus-induced interferon in having an apparent molecular weight of 90,000 (14) .
Interferon induced by helenine, like that induced by statolon, possesses most of the characteristics of virus-induced interferon. The kinetics of its appearance in the serum follow those of NDV-induced interferons in that a maximum titer appears in 12 hr (6, 9) . No information is yet available, however, on its molecular weight or on the effect of such inhibitors as actinomycin D on its formation.
The active principle in helenine is still a matter of conjecture since it has not been obtained in a sufficiently pure form to permit definite identification. According to previous analysis, preparations of helenine contain both nucleoproteins (16) and polysaccharides (17) , both of which have been shown to be capable of inducing interferon formation (12, 13, 6) .
Because of technical difficulties incidental to production of interferon of human origin in sufficient amounts, prospects for prophylactic and therapeutic trials with exogenous interferon are not good at the present time. It has been suggested that a possible clinical approach may be through induction of endogenous interferon in man (18) . In this relation, substances like helenine may hold great promise.
SUMMARy
Helenlne, a substance obtained from broth cultures of Penicillium funiculosum and known to exert a protective effect in vivo in experimental animals against several unrelated viruses, has been shown to elicit the formation in cell cultures and in intact mice of an inhibitor of viral plaque formation.
Because the biological and chemical characteristics of the viral inhibitor in-duced by helenine are similar to those of interferon, it is suggested that the antiviral effect of helenine may be mediated through the formation of interferon.
